OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr McCann on the Importance of Integrating Patient Preferences Into Treatment Planning for Patients With HER2+ Breast Cancer

August 25th 2025

Kelly McCann, MD, PhD, discusses the relevance of patient preferences during treatment decision-making for patients with HER2-positive breast cancer.

Dr Wang on Evolving Challenges in the Management of CRPC

August 22nd 2025

Jue Wang, MD, discusses the evolving challenges in the management of castration-resistant prostate cancer.

Dr Cardoso on Outcomes With Elinzanetant for Hot Flashes in HR+ Breast Cancer

August 22nd 2025

Fatima Cardoso, MD, MSc, FESMO, discusses quality-of-life outcomes with elinzanetant for the management of hot flashes in hormone receptor–positive breast cancer.

Dr Kremyanskaya on the Ongoing Development of Divesiran for Polycythemia Vera

August 22nd 2025

Marina Kremyanskaya, MD, PhD, discusses early-phase findings with divesiran in patients with polycythemia vera.

Dr Deng on the Role of MSH6 in Modulating PARP Inhibitor Sensitivity in BRCA-Proficient High-Grade Serous Ovarian Cancer

August 22nd 2025

Ou Deng, PhD, discusses research aimed at clarifying the role of MSH6 in modulating sensitivity to PARP inhibitors in patients with BRCA-proficient HGSOC

Dr Abu Rous on the Timing of HER2 and MET Testing in NSCLC

August 22nd 2025

Fawzi F Abu Rous, MD, discusses evolving strategies for HER2 and MET testing in non–small cell lung cancer.

Dr Lai on Post-Induction Treatment Strategies in mCRC

August 22nd 2025

Connie Lai, MD, discusses an analysis of post-induction maintenance vs treatment break in metastatic colorectal cancer.

Dr Dreyling on the Efficacy of Frontline Acalabrutinib Plus BR in High-Risk MCL

August 21st 2025

Martin Dreyling, MD, PhD, discusses the efficacy of first-line acalabrutinib plus BR in high-risk patients with mantle cell lymphoma.

Dr Shah on Safety and Efficacy Outcomes With Obe-Cel in Older R/R ALL

August 21st 2025

Bijal Shah, MD, MS, discusses key safety and efficacy outcomes from a post hoc analysis of the FELIX trial of obe-cel in relapsed/refractory B-ALL.

Dr Sidana on the Efficacy of Second-Line Cilta-Cel in Relapsed/Refractory Myeloma

August 21st 2025

Surbhi Sidana, MD, discusses the PFS and OS benefit of second-line cilta-cel in patients with relapsed/refractory multiple myeloma.

Dr Wainberg on Treatment Updates in Gastric Cancer and Biliary Tract Cancer

August 21st 2025

Zev A. Wainberg, MD, MSc, highlighted notable research in gastric cancer and cholangiocarcinoma presented during the 2025 ESMO GI Congress.

Dr Powles on the Role of the CREST Study in Future Clinical Trial Design in BCG-Naive NMIBC

August 21st 2025

Thomas Powles, MBBS, MRCP, MD, discusses how future clinical trials could leverage the CREST trial as a basis for BCG-naive NMIBC treatment development.

Dr Marshall on the Role of Fruquintinib in the Treatment Paradigm for mCRC

August 20th 2025

John L. Marshall, MD, discusses the use of fruquintinib in the treatment of patients with metastatic colorectal cancer.

Dr Martini on the Clinical Significance of Nadofaragene Firadenovec in BCG–Unresponsive NMIBC

August 20th 2025

Alberto Martini, MD, discusses the current optimal role of nadofaragene firadenovec in the BCG-unresponsive NMIBC treatment paradigm.

Dr Chahoud on the Rationale for Evaluating Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC

August 20th 2025

Jad Chahoud, MD, MPH, discusses the background and rationale for evaluating zanzalintinib plus nivolumab with or without relatlimab in ccRCC.

Dr Gupta on Updated Efficacy Data With Liso-Cel in Second-Line Relapsed/Refractory LBCL

August 19th 2025

Supriya Gupta, MD, discusses updated efficacy data on liso-cel as second-line therapy for large B-cell lymphoma.

Dr Ku on the Rationale for Evaluating JNJ-90014496 in Relapsed/Refractory LBCL

August 19th 2025

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.

Dr Wang on Reducing Treatment Discontinuation in Older Patients With mCRPC

August 19th 2025

Jue Wang, MD, discusses the challenge of treatment discontinuation in older patients with metastatic castration-resistant prostate cancer.

Dr Randall on the Complexity of PEComas

August 19th 2025

R. Lor Randall, MD, FACS, discusses the complexity of perivascular epithelioid cell tumors and the critical importance of multidisciplinary care.

Dr Halmos on Selection Criteria for Adjuvant Therapy After Chemo/IO in NSCLC

August 19th 2025

Balazs Halmos, MD, shares suggestions regarding patient selection for adjuvant therapy after neoadjuvant chemoimmunotherapy and surgery in NSCLC.